logo
How the Airbus A321XLR is changing the air map of the world

How the Airbus A321XLR is changing the air map of the world

CNN13-02-2025
Nashville's honky-tonks are going to get a little busier in April.
That's when Aer Lingus launches its first nonstop flight to the country music capital from Ireland, a lesser-known hotbed of country music fans.
The new flight to Nashville from Dublin is possible with a new, longer-range plane from Airbus: the A321XLR, or 'Extra Long Range.'
The derivative of the popular A321neo that debuted in 2017 can fly further than any other single-aisle plane on the market. Airbus also says it burns 30% less fuel per seat than previous-generation aircraft.
'It allows us to go to cities that we would not be able to take the risk on with a wide-body,' said Reid Moody, chief strategy and planning officer at Aer Lingus, referring to the twin-aisle aircraft such as the Airbus A330 or Boeing 787 that are common on transatlantic flights.
The Irish carrier already flies two A321XLRs and plans to add four more by the end of the year.
Hundreds of planes on order
Airlines around the world are clamoring for the new plane.
Aer Lingus and its Spanish peer, Iberia — both are owned by European airline conglomerate International Airlines Group (IAG) — already fly the A321XLR, and Airbus has firm orders for more than 500 of the model, data from aviation analytics firm Cirium shows.
Air Canada, American Airlines, Qantas Airways and United Airlines are among those awaiting their first XLR.
Single-aisle planes across the North Atlantic are not new.
Boeing's 757 has plied the skies between North America and Europe for decades. The aircraft, however, is old. The last plane rolled off the production line in Everett, Washington, in 2004.
The remaining airlines that fly the 757, including United, are eager to replace them with the new, fuel-sipping XLRs. And others, such as Aer Lingus, want the new Airbus model to expand their transatlantic map to new cities.
The XLR, once it replaces older 757s, should allow airlines to bypass major hubs on either side of the Atlantic and open new, nonstop, transatlantic routes to smaller cities.
'We're going to open up 10 to 12 new cities in Eastern Europe (and) North Africa out of Newark and (Washington) Dulles,' United CEO Scott Kirby said on The Air Show podcast in June. 'We're excited about it.'
While Kirby didn't reveal just what cities United is considering, its recent expansion plans hint at outside-the-box destinations, at least from the United States, such as Bilbao, Spain, and Nuuk, Greenland.
United expects its first of 50 A321XLRs in early 2026.
American Airlines is also eyeing Europe with its coming XLRs.
'We are looking at new, secondary Spain, Portugal, UK, anything in range — France, Germany, Scandinavia, all these smaller destinations that we think a wide-body just isn't well-suited for,' Brian Znotins, who leads network planning at American, told The Points Guy in November.
American's first XLR, which is due later this year, will initially be used on premium transcontinental flights between New York and both Los Angeles and San Francisco.
In addition to expansion opportunities, travelers could also see airlines using their XLRs to add extra flights on routes that might have only one today. Or the plane could be used to extend a seasonal route; for example, one that flies only during the summer, to year-round status by flying during the lower-demand winter.
Just how many new transatlantic and other routes the XLR will unlock is an open question.
Safety modifications required by European regulators added weight to the plane. It's widely acknowledged that the changes have reduced the estimated range of the jet to around 5,200 miles (4,500 nautical miles) from up to 5,400 miles (4,700 nautical miles).
The range cut, while seemingly small, could mean the difference between flying from New York to most of Europe versus just Western Europe.
'The XLR is absolutely heavier than Airbus wanted it to be originally,' said Jon Ostrower, editor of The Air Current, on a recent episode of The Air Show. 'That really affected the heavily loaded long-range operations that airlines like Frontier wanted with 240 seats.'
Discounter Frontier Airlines canceled its order for the XLR in August citing performance concerns.
'The airplane likely won't have the range to do some of the routes people have hoped to see, like East Coast to Rome,' said Brett Snyder, president of the travel assistance service Cranky Concierge and author of the Cranky Flier blog. 'But it is enabling flying including Dublin to Nashville and Indianapolis. Over time, there will be more opportunity to stretch and try new things.'
Most airlines seem unconcerned over the range cut.
'It's only a concern during the peak summers,' says Ramiro Sequeira, the chief operating officer of Iberia, of the A321XLR's capabilities. The carrier believes it can do everything it hoped to with the plane — if not more.
Iberia was the first to fly the XLR, debuting the plane on flights between Madrid and Boston in November. It plans to introduce it in April on flights to Washington, D.C., pending the delayed delivery of its second aircraft from Airbus.
Sequeira hasn't revealed what's next for the plane at Iberia. 'New routes are the secret of the commercial department,' he says.
Travelers can expect a product on board the XLR similar to what they would see on a larger plane.
American plans to introduce a new business class and premium economy product on its A321XLRs when they debut later this year. The airline will outfit the planes with 20 of its new lie-flat 'Flagship Suites' up front, 12 spacious premium economy seats in the middle, and an updated economy product in the back.
'We're really pleased (about) the introduction of our new Flagship Suite,' American CEO Robert Isom told investors on January 23, citing the XLR as among the first planes to receive the seats. He emphasized that passenger comfort was important on planes that will fly longer international routes.
Aer Lingus and Iberia outfitted their planes with lie-flat business class seats up front and standard economy seats in back. And customer feedback, they said, is largely positive.
'The customer,' Moody said, 'for all intents and purposes, doesn't mind traveling on the narrow-body versus the wide-body.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Promising Penny Stocks To Consider In August 2025
Promising Penny Stocks To Consider In August 2025

Yahoo

time16 hours ago

  • Yahoo

Promising Penny Stocks To Consider In August 2025

As the U.S. stock market continues its rally, with major indices like the S&P 500 and Nasdaq hitting new highs, investors are exploring diverse opportunities to capitalize on this momentum. Penny stocks, often associated with smaller or newer companies, remain a compelling area for those looking to uncover hidden value and growth potential. Despite being an older term in the investment lexicon, these stocks can offer intriguing opportunities when backed by robust financials and strategic positioning within their industries. Top 10 Penny Stocks In The United States Name Share Price Market Cap Financial Health Rating Waterdrop (WDH) $1.83 $679.93M ★★★★★★ WM Technology (MAPS) $1.27 $192.5M ★★★★★★ Talkspace (TALK) $2.58 $432.07M ★★★★★★ Performance Shipping (PSHG) $1.90 $22.88M ★★★★★★ Tuniu (TOUR) $0.9326 $89.67M ★★★★★★ CI&T (CINT) $4.86 $662.14M ★★★★★☆ BAB (BABB) $0.9288 $6.57M ★★★★★★ Lifetime Brands (LCUT) $3.95 $92.44M ★★★★★☆ Resources Connection (RGP) $4.93 $151.7M ★★★★★★ TETRA Technologies (TTI) $3.92 $529.12M ★★★★★★ Click here to see the full list of 400 stocks from our US Penny Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Erasca Simply Wall St Financial Health Rating: ★★★★★★ Overview: Erasca, Inc. is a clinical-stage precision oncology company dedicated to discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers, with a market cap of approximately $442.49 million. Operations: Erasca, Inc. currently does not report any revenue segments. Market Cap: $442.49M Erasca, Inc., a pre-revenue clinical-stage precision oncology company, recently reported a reduced net loss of US$33.88 million for Q2 2025 compared to the previous year. Despite being unprofitable with negative return on equity and no significant revenue streams, the company remains debt-free and has sufficient cash runway for over two years. Recent developments include FDA clearance for an investigational drug targeting KRAS-mutant tumors and filing a US$500 million shelf registration to potentially raise capital through various securities. The stock exhibits high volatility but has not experienced meaningful shareholder dilution recently. Take a closer look at Erasca's potential here in our financial health report. Review our growth performance report to gain insights into Erasca's future. EVgo Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: EVgo, Inc. owns and operates a direct current fast charging network for electric vehicles in the United States, with a market cap of approximately $1.16 billion. Operations: The company's revenue is derived from its Retail - Gasoline & Auto Dealers segment, totaling $308.37 million. Market Cap: $1.16B EVgo, Inc., with a market cap of US$1.16 billion, is expanding its fast charging network for electric vehicles in the U.S., supported by a recent US$225 million credit facility from global banks. Despite being unprofitable and experiencing increased losses over the past five years, EVgo's revenue is projected to grow significantly. The company reported Q2 2025 sales of US$98.03 million, up from US$66.62 million a year ago, though net losses widened to US$13 million. While short-term liabilities are covered by assets, long-term liabilities remain uncovered; insider selling has been significant recently. Navigate through the intricacies of EVgo with our comprehensive balance sheet health report here. Gain insights into EVgo's future direction by reviewing our growth report. Sana Biotechnology Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Sana Biotechnology, Inc. is a biotechnology company that focuses on utilizing engineered cells as medicines in the United States, with a market cap of approximately $791.90 million. Operations: Sana Biotechnology, Inc. currently does not report any revenue segments. Market Cap: $791.9M Sana Biotechnology, Inc., with a market cap of US$791.90 million, remains pre-revenue and unprofitable but has managed to reduce losses over the past five years by 4.5% annually. The company recently reported a net loss of US$93.8 million for Q2 2025, up from US$50.29 million the previous year, and completed a follow-on equity offering raising approximately US$75 million to extend its cash runway beyond five months. Despite high volatility in its share price and short-term assets not covering long-term liabilities, Sana's strategic advancements include promising clinical results for its hypoimmune technology in diabetes treatment studies. Dive into the specifics of Sana Biotechnology here with our thorough balance sheet health report. Assess Sana Biotechnology's future earnings estimates with our detailed growth reports. Next Steps Get an in-depth perspective on all 400 US Penny Stocks by using our screener here. Contemplating Other Strategies? AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ERAS EVGO and SANA. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati

3 Promising Penny Stocks With At Least $200M Market Cap
3 Promising Penny Stocks With At Least $200M Market Cap

Yahoo

time16 hours ago

  • Yahoo

3 Promising Penny Stocks With At Least $200M Market Cap

As the S&P 500 and Nasdaq Composite reach record highs, driven by optimism around potential interest rate cuts, investors are increasingly exploring diverse avenues for growth. Penny stocks, a term that traditionally refers to low-priced shares of smaller or newer companies, remain an intriguing segment of the market due to their potential for significant returns when backed by solid financials. In this article, we'll examine three penny stocks that demonstrate strong financial health and offer promising opportunities for those interested in under-the-radar investments with long-term potential. Top 10 Penny Stocks In The United States Name Share Price Market Cap Financial Health Rating Waterdrop (WDH) $1.88 $669.08M ★★★★★★ WM Technology (MAPS) $1.13 $204.42M ★★★★★★ Puma Biotechnology (PBYI) $4.87 $245.31M ★★★★★★ Performance Shipping (PSHG) $1.84 $22.88M ★★★★★★ Tuniu (TOUR) $0.9326 $88.89M ★★★★★★ CI&T (CINT) $4.96 $696.85M ★★★★★☆ BAB (BABB) $0.904375 $6.46M ★★★★★★ Lifetime Brands (LCUT) $4.08 $82.7M ★★★★★☆ Resources Connection (RGP) $4.55 $149.03M ★★★★★★ TETRA Technologies (TTI) $3.97 $522.46M ★★★★★★ Click here to see the full list of 411 stocks from our US Penny Stocks screener. Below we spotlight a couple of our favorites from our exclusive screener. Maravai LifeSciences Holdings Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Maravai LifeSciences Holdings, Inc. is a life sciences company that offers products supporting the development of drug therapies, vaccines, cell and gene therapies, and diagnostics across various global regions with a market cap of $524.60 million. Operations: Maravai LifeSciences Holdings, Inc. has not reported specific revenue segments. Market Cap: $524.6M Maravai LifeSciences Holdings, Inc. has experienced significant challenges recently, with a net loss of US$39.59 million in Q2 2025 and a goodwill impairment charge of US$30.45 million. The company's short-term assets exceed both its long-term and short-term liabilities, providing some financial stability despite ongoing unprofitability and high volatility in share price. Recent executive changes aim to drive strategic growth and profitability, but the suspension of revenue guidance for 2025 reflects uncertainty amid leadership transitions. Despite these hurdles, Maravai's debt-to-equity ratio has improved significantly over five years, indicating progress in managing financial leverage effectively. Jump into the full analysis health report here for a deeper understanding of Maravai LifeSciences Holdings. Assess Maravai LifeSciences Holdings' future earnings estimates with our detailed growth reports. 3D Systems Simply Wall St Financial Health Rating: ★★★★★☆ Overview: 3D Systems Corporation offers 3D printing and digital manufacturing solutions across various regions worldwide, with a market cap of approximately $225.72 million. Operations: The company has not reported any specific revenue segments. Market Cap: $225.72M 3D Systems Corporation, with a market cap of US$225.72 million, recently reported Q2 2025 earnings showing revenue of US$94.84 million and net income of US$104.44 million, reversing a prior year's loss. However, the company remains unprofitable overall and faces high share price volatility. Despite this, its short-term assets significantly exceed liabilities, providing some financial cushion. The introduction of innovative products like the NextDent Jetted Denture Solution and FDA-approved bioprinting technologies highlights potential growth avenues amidst legal challenges from a class action lawsuit alleging misleading statements about business operations and financial health during challenging industry conditions. Get an in-depth perspective on 3D Systems' performance by reading our balance sheet health report here. Review our growth performance report to gain insights into 3D Systems' future. SelectQuote Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: SelectQuote, Inc. operates a technology-enabled, direct-to-consumer distribution platform for selling insurance policies and healthcare services in the United States, with a market cap of approximately $331.62 million. Operations: The company's revenue is primarily derived from its Senior segment at $632.07 million, Healthcare Services at $673.90 million, and Life insurance at $167.07 million. Market Cap: $331.62M SelectQuote, Inc., with a market cap of US$331.62 million, operates in the insurance and healthcare services sector. It faces challenges due to a securities class action lawsuit alleging misleading business practices, which could impact its reputation and legal standing. Despite being unprofitable, SelectQuote has a robust cash runway exceeding three years due to positive free cash flow growth. Its short-term assets cover liabilities but not long-term debt. Recent strategic initiatives include expanding its SelectRx service to improve medication adherence among Medicare beneficiaries, demonstrating commitment to enhancing health outcomes and potentially bolstering future revenue streams amidst ongoing legal issues. Click here and access our complete financial health analysis report to understand the dynamics of SelectQuote. Examine SelectQuote's earnings growth report to understand how analysts expect it to perform. Next Steps Click here to access our complete index of 411 US Penny Stocks. Curious About Other Options? The end of cancer? These 26 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include MRVI DDD and SLQT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio

HF Foods Group And 2 Other Promising Penny Stocks For Your Watchlist
HF Foods Group And 2 Other Promising Penny Stocks For Your Watchlist

Yahoo

time16 hours ago

  • Yahoo

HF Foods Group And 2 Other Promising Penny Stocks For Your Watchlist

The U.S. stock market has recently experienced a slight dip from record highs, influenced by inflation concerns that have tempered expectations for interest rate cuts. In this context, investors often seek opportunities in less conventional areas of the market, such as penny stocks. Although the term 'penny stocks' might seem outdated, these smaller or newer companies can still offer significant growth potential when backed by strong financials. Top 10 Penny Stocks In The United States Name Share Price Market Cap Financial Health Rating Waterdrop (WDH) $1.83 $679.93M ★★★★★★ WM Technology (MAPS) $1.27 $192.5M ★★★★★★ Talkspace (TALK) $2.58 $432.07M ★★★★★★ Performance Shipping (PSHG) $1.90 $22.88M ★★★★★★ Tuniu (TOUR) $0.9326 $89.67M ★★★★★★ CI&T (CINT) $4.86 $662.14M ★★★★★☆ BAB (BABB) $0.9288 $6.57M ★★★★★★ Lifetime Brands (LCUT) $3.95 $92.44M ★★★★★☆ Resources Connection (RGP) $4.93 $151.7M ★★★★★★ TETRA Technologies (TTI) $3.92 $529.12M ★★★★★★ Click here to see the full list of 401 stocks from our US Penny Stocks screener. Here we highlight a subset of our preferred stocks from the screener. HF Foods Group Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: HF Foods Group Inc. operates as a marketer and distributor of specialty food products, seafood, fresh produce, frozen and dry food, and non-food items to Asian restaurants and other foodservice customers in the United States, with a market cap of approximately $176.54 million. Operations: The company generates revenue primarily through its wholesale grocery segment, which amounted to $1.22 billion. Market Cap: $176.54M HF Foods Group, with a market cap of US$176.54 million, reported Q2 2025 sales of US$314.85 million and net income of US$1.22 million, showing improvement from the previous year despite remaining unprofitable overall. The company has a stable cash runway exceeding three years and continues to generate positive free cash flow, though it faces high debt levels with a net debt to equity ratio of 62.7%. Recent board changes include the appointment of Dennis Lam as an independent director and audit committee chair, suggesting ongoing governance improvements amidst management's relatively short tenure at the company. Dive into the specifics of HF Foods Group here with our thorough balance sheet health report. Review our growth performance report to gain insights into HF Foods Group's future. WM Technology Simply Wall St Financial Health Rating: ★★★★★★ Overview: WM Technology, Inc. operates as an online cannabis marketplace offering ecommerce and compliance software solutions to retailers and brands in the cannabis industry across the United States and internationally, with a market cap of approximately $192.50 million. Operations: WM Technology generates revenue primarily from its Software & Programming segment, amounting to $183.68 million. Market Cap: $192.5M WM Technology, Inc., with a market cap of US$192.50 million, reported Q2 2025 sales of US$44.85 million and net income of US$1.43 million, reflecting profitability despite a slight revenue decline from the previous year. The company is debt-free and has stable short-term assets exceeding liabilities, though it was recently dropped from the Russell 2000 indices. Its share price has been highly volatile over the past three months, and there was significant insider selling in recent months. Despite these challenges, WM Technology trades at good value compared to its peers and industry estimates. Click to explore a detailed breakdown of our findings in WM Technology's financial health report. Gain insights into WM Technology's outlook and expected performance with our report on the company's earnings estimates. Dingdong (Cayman) Simply Wall St Financial Health Rating: ★★★★★★ Overview: Dingdong (Cayman) Limited is an e-commerce company operating in China with a market cap of approximately $443.61 million. Operations: The company generates revenue primarily from its online retail operations, totaling CN¥23.52 billion. Market Cap: $443.61M Dingdong (Cayman) Limited, with a market cap of approximately US$443.61 million, reported Q1 2025 revenue of CN¥5.48 billion and net income of CN¥5.62 million, marking profitability despite a slight decline in net income from the previous year. The company holds more cash than its total debt and maintains short-term assets exceeding liabilities, indicating financial stability. Trading at nearly 97% below estimated fair value suggests potential undervaluation relative to peers. Profitability has improved over the past five years with significant earnings growth, although high return on equity is influenced by elevated debt levels. Jump into the full analysis health report here for a deeper understanding of Dingdong (Cayman). Explore Dingdong (Cayman)'s analyst forecasts in our growth report. Where To Now? Click this link to deep-dive into the 401 companies within our US Penny Stocks screener. Searching for a Fresh Perspective? Uncover 15 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include HFFG MAPS and DDL. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store